Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic CancerTalia Golan, Hedy L. Kindler, Pascal Hammel et al.|New England Journal of Medicine|2019Cited by 2.2k
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupDominik Paul Modest, Anke Reinacher‐Schick, Ingrid Ricard et al.|Annals of Oncology|2016Cited by 344
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerHedy L. Kindler, Talia Golan, Pascal Hammel et al.|Journal of Clinical Oncology|2022Cited by 224
<i>TFAP2E–DKK4</i> and Chemoresistance in Colorectal CancerMatthias Ebert, Roland M. Schmid, Catherine Lofton–Day et al.|New England Journal of Medicine|2012Cited by 184
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus PaperBernhard Wörmann, Ralf‐Dieter Hofheinz, Carsten Bokemeyer et al.|Oncology Research and Treatment|2020Cited by 88